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http://dx.doi.org/10.1016/j.chembiol.2013.01.008We live immersed in a world of big data.
Every Internet click is tracked and
noted—where we browse, what we
view, how long we browse, where we
shop, what we buy, what we ‘‘like.’’ In
fact, many of our daily activities are moni-
tored. Surveillance cameras track vehi-
cles as they pass through intersections
and track pedestrians as they walk down
sidewalks; cameras note our transactions
at ATMs. While it’s understandable to
worry that so much surveillance invades
our privacy, we may be overlooking the
most personal information of all: the order
of base pairs in our genomes. Each day,
DNA sequencers worldwide churn outMedical charts in the future may contain the full sequence of our
genomes in addition to the notes our physicians type into
a keyboard.personal genomic data, which are then
folded into large databases, some of
which are open access, others of which
are privately held. All of these big data
collections carry value, and they’re mined
for that value, whether it’s to tell Amazon
what kind of books we like or to tell
researchers whether our DNA carries vari-
ations that link to an increased risk for
disease.
‘‘I do think that those are parallel
discussions,’’ says Mark Gerstein, PhD,
a professor of bioinformatics at Yale
University in New Haven. ‘‘But if you talk
to most genomicists they don’t usually
connect genomics with large-scale data
mining on the web or in life.’’
They’re the same, Gerstein says.
People may be attuned to the concept of
secrets and privacy of personal informa-
tion but not when it comes to mining tera-
bytes of personal genomic information.
The distinction is critical, because our
tastes in books and music may evolve
over the years, but our genomes never
change.Medical charts in the futuremay contain
the full sequence of our genomes in addi-
tion to the notes our physicians add.
Folding our genomic information into our
medical histories may one day help physi-
cians treat whatever ails us in a targeted
way—at least, that’s the hope of person-
alized medicine—searching our genomes
for variations that signal our risk of
disease, for example, to target therapies
for our particular cancer. But the push
by researchers to obtain the full genetic
sequence of people in every corner of
the world brings both the hope that
personalized medicine will reach its
potential and the worry that the privacyof each individual’s genome—our most
personal information —won’t really be
private at all.
Linking gene variants to disease risk is
already saving lives (think the BRCA1
and 2 mutations and risk for breast
cancer). In the future, variants along the
genome may be able to identify more
than just disease risk: the variants unique
to each of usmaymake our identities easy
to figure out. This concern carries the
weight of ethical, legal, and regulatory
issues that have not been fully addressed.
With the completion of the Human
Genome Project came the worry that
peoplewould be facedwith discrimination
based on their genetic makeup. In 2008,
President George W. Bush signed the
Genetic Information Non-Discrimination
Act (GINA) into law. GINA protects Amer-
icans against discrimination in the areas
of employment and medical insurance
based on their genetic information. GINA
does not cover life insurance or discrimi-
nation in other potential areas such as
housing. Our medical privacy is coveredChemistry & Biology 20, January 24, 20under the Health Insurance Portability
and Accountability Act, or HIPPA.
A handful of states are either proposing
or enacting legislation that moves beyond
GINA. In January 2012, California enacted
SB559, which protects residents from
genetic discrimination not only in employ-
ment and health insurance (which GINA
covers) but in housing, life insurance,
mortgage lending, and elections. Other
states, including New York, Alabama,
and Massachusetts, are proposing their
own legislation.
‘‘HIPPA and laws governing the use of
genomic information like GINA are still
quite relevant. What we’re finding is that
people have taken a step back and asked
‘how can the community simultaneously
advance medical knowledge, and provide
security and confidentiality for people
who are contributing their medical and
genomic data?’ This is still a work in
progress,’’ says Scott D. Kahn, PhD,
vice president and chief information
officer at Illumina, Inc., headquartered in
San Diego, Califonria.
The three issues that most need to be
addressed are the legalities of intellectual
property (who owns our genomes and can
gene variations be patented), medical
privacy in clinical settings related to
HIPPA, and legalities and policy changes
necessary to support the research world,
says Jeffrey Kahn, PhD, MPH, deputy
director of the Johns Hopkins Berman
Institute of Bioethics in Baltimore, Mary-
land. HIPPA gets tricky, Kahn says,
because of informed consent agree-
ments. People who join research projects
sign an informed consent document that
grants researchers permission to use, for
example, what may be contained in a bit
of tissue or blood sample. For genomics
research, consent varies by entity collect-
ing the data.
For example, those who join the
National Institutes of Health’s 1000
Genomes project, which is stored on
Amazon’s web services, agree to make13 ª2013 Elsevier Ltd All rights reserved 1
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people who sign up to have their DNA
scanned with 23andMe agree to have
their genetic information added to the
company’s private research database. In
such cases, HIPPA privacy may not apply
in relation to their genomic information,
because they’ve consented to public use
of the data, Kahn says.
Currently, the Supreme Court is ruling
on whether human genes may be
patented in a case relating to Myriad
Genetics, the Utah-based company that
has exclusive US testing rights for
the BRCA1 and 2 mutations. Even if the
Supreme Court rules against Myriad, the
company will still own its valuable
database.
Rethinking Privacy?
Thanks to next-generation sequencers
such as the HiSeq 2500, the amount of
personal genomic data has doubled every
9months over the past few years. In 2011,
the output was 40 GB per day. Now the
output nears 140 GB per day. The ability
to analyze this data is also keeping pace
thanks to new algorithms that help align
and assemble the bases and identify the
unique differences in the sequence data,
states Scott Kahn of Illumina.
The size of the databases makes
encryption for privacy and sharing more
burdensome because data are too big to
transfer. Given the increasingly revealing
nature of the data, Gerstein worries that
access to some databases will become
limited, and this will encumber small labs
interested in genomics research. The
worry is that unique variations along
each person’s genome will make anony-
mized research subjects somehow identi-
fiable and people would be able to fish out
information they weren’t intended to get
access to in the first place.
Right now, says Illumina’s Kahn, such
reidentification would be difficult. ‘‘If I
gave an expert in the field a genome,
they would be hard pressed to identify
that person. The genome can only predict
height, hair, and eye color in broad terms
and with statistical variations, and we
cannot construct the individual only from
his or her genomic data. On the other
hand, if I have an individual’s DNA2 Chemistry & Biology 20, January 24, 2013 ªsequence data from his or her blood or
saliva, I can compare this data to the
unknown genome to determine if they
are equivalent.’’
The very potential for that comparison
is exactly what worries Gerstein. Even
though genomic databases are anony-
mized, the allele frequencies, for example,
could be linked with some disease or
phenotype that characterizes the group
as a whole. The potential to reidentify
those individuals exists. ‘‘If you happened
to shake a hand, swab the sample, and do
PCR suddenly, the potential exists to
connect that person who left that bit of
DNA with the huge amount of analyzed
genome data up in the cloud,’’ he says.
In the future, as algorithms improve and
researchers understand the significance
of variants, for example, more and more
personally identifying information will be
able to bemined, and so signing a consent
form now has ramifications for the future.
Even if people sign a consent form that
gives researchers full access to their
genomes, their children haven’t con-
sented, says Gerstein. In addition, there’s
also very little privacy protection now in
relation to dead people. ‘‘We can se-
quence the DNA of a dead person, but
that dead person may have children, and
we’ve really violated those children’s
privacy, but the law doesn’t speak very
much to that,’’ says Gerstein. ‘‘Mining
personal genomes in 20 years might find
a lot more information than it does now.
That creates a whole new set of privacy
aspects,’’ Gerstein says.
There are solutions to protecting
privacy, says Illumina’s Kahn. Genomic
data can be summarized and, rather
than providing information on one patient,
the data can be pooled into cohorts in
such a way that researchers can advance
knowledge while still allowing for personal
privacy. Gerstein and colleagues also
proposed computational approaches to
privacy solutions (Greenbaum et al.,
2011). The authors suggest, for example,
‘‘slicing’’ out specific variants from a large
data sets, summarizing the data, or using
allele frequency to filter specific areas of
interest. The authors noted, ‘‘however,
one should keep in mind that although
this reduces the public exposure of the2013 Elsevier Ltd All rights reservedsequences, none of these data manipula-
tion methods fully deidentifies the test
subjects.’’
‘‘The privacy has a tremendous cost. It
really impedes the research. Each incre-
mental thing you do to protect the infor-
mation, even if you release the data with
some protection, every bit of protection
exacts a cost in terms of time and money
and becomes unbearable at some point,’’
says Jeffrey Kahn of Johns Hopkins.
Another solution, he says, is to think about
privacy differently. ‘‘The idea of protecting
information from anybody but your doctor
and hospital may not work anymore. So
much of private information is available
outside of medical setting that it may not
make a ton of sense to think about
medical information as distinct and sepa-
rate,’’ says Kahn. Instead of thinking
about all-out privacy, think about control
of access to some but not all of your infor-
mation. The extreme end, Kahn suggests,
would be to say there’s no way to protect
people’s privacy, so we would need to
create a new legal regime that will funda-
mentally recognize the fact that our lives
are not as private as we think. Then every-
one’s personal genome could be posted
in the cloud on the web but with some
sort of legal protections in place.
The latter approach would be difficult,
Kahn continues, in that the genome
sequencing effort is worldwide and laws
as well as attitudes toward privacy differ
by country. The IP issue complicates
matters as well. Private companies such
as 23andMe and Myriad own their
databases.
Genome sequencing is ‘‘one of coolest
technologies we have, and one of most
useful we have, for doing medical
research. There’s the privacy issue and
there’s an obvious social good, so that’s
hard to put those two things together,’’
says Kahn.REFERENCE
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